Roche Holding AG

Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker fights to regain investor confidence in its …

Zealand Pharma Outlines Ambitious 5-Year Obesity Drug Strategy Amidst Growing Competition Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for it’s anti-obesity portfolio …